
|Videos|March 14, 2022
What the re:Vive 2.0 platform may mean for the future of vision diagnostics
Author(s)Sheryl Stevenson
Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.
Advertisement
Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director.
Advertisement
Latest CME
Advertisement
Advertisement




















